Ophthalmopathy
19
3
3
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.3%
1 terminated out of 19 trials
91.7%
+5.1% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (19)
Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Assessing Agreement Between Acuvera Capture and Paper-Based Methods for BCVA Data Recording in Ophthalmic Trials
Assessment of the Ocular Microbiome in Health and Disease
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
Comparison Between Peribulbar And Sub-tenon Blocks on Oculocardiac Reflex (OCR) During Pediatric Strabismus Surgery
Effect Of Reusing the Operative Supplies On Cataract Surgery and Climate Change
Evaluating Medium-chain Triglycerides as a Temporary Intraocular Tamponading Agent for Retinal Detachment
Refractive Transepithelial Photo-keratectomy (T-PKR) in High Myopia
Autologous Blood for Full-thickness Macular Hole
Single Superior ILM/ERM Flap for the FTMH.
Phaco-Trabeculotomy Vs Phaco-Trabeculectomy
Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment
Ocular Manifestations of Inflammatory Bowel Disease
Assessment of COVID-19 in Tearfilm
Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)
Validation of the Utility of Ophthalmology Intelligent Diagnostic System
Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction
Validation of the Utility of an Intelligent Visual Acuity Diagnostic System for Children
Artificial Intelligence Screening on Patients With Primary Angle Closure Glaucoma